-
They used some abbreviations in the manuscript which have not been adequately described and could be misleading for the readers (such as LIL, SPIRIT, DTM treatment, UNINOVE, etc). -At the moment, I cannot comment the Result and Discussion sections because there are not present. But if I understood instructions for reviewers from the Editors it is OK for ongoing studies. -
The references have not been written in the style of the Journal and should be checked and adapted to it. -I am not native speaker for the English language, so I do not have a merit to judge it. To me, the language "sounds" OK. -I would encourage a cost-effectiveness analysis of different treatment modalities for myofascial TMD pain, but some clarifications should be done in the manuscript before.
REVIEWER
Hilbert van der Glas The Dental School, University of Dundee, UK REVIEW RETURNED 02-Oct-2017
GENERAL COMMENTS
Referee report on 'Photomodulation in the treatment of pain in patients with TMD: protocol for cost-effectiveness analysis (Manuscript ID: bmjopen-2017-018326; authors: Sobral et al.) General remarks:
The aim of the study is (1) to evaluate the effectiveness of treatments with low-intensity laser and occlusal splint for muscle pain in patients with TMD with a placebo sham-laser treatment as control, (2) to determine the direct costs of treatment, and (3) to compare the cost-effectiveness of both types of treatment by determining the ratio between the amount of direct costs and the improvement in an outcome variable of pain intensity. Furthermore, the effect of treatment will be determined on Health-related Quality of Life (HR-QoL), using EuroQol (EQ-5D).
It is relevant to evaluate clinical and economic data together in sight of decision making and to compare laser treatment with splint therapy (a common type of therapy in Dentistry). Furthermore, it is interesting to carry out sham-laser treatment as placebo, also for comparison with splint therapy. However, clarification and further considerations are needed regarding the following issues.
First, laser treatment includes, according to the proposed protocol, an initial phase in which this treatment is applied twice a week for 6 weeks, and then twice a month up to 12 months. Splint therapy includes wearing of an occlusal splint at night for 12 months. However, fixed treatment durations of 12 months are not in accordance with general clinical care. Durations of laser treatment of 2-8 weeks have been reported in the literature while the intended duration of occlusal splint therapy varies between 12-30 weeks; the mean duration of splint therapy is 24.2 weeks (cf. your ref# 40: van Grootel et al., BMC Musculoskeletal Disorders. 2017; 18:76) . Hence, apart from over-treatment of many patients, your proposed long treatment duration of 12 months will yield biased outcomes of costeffectiveness.
Second, it is not sufficient to consider an overall improvement in, for example, pain outcome, because pain and other signs and symptoms of myogenous TMD are reduced to residual levels in only part of the patients, with a 'successful' treatment. Following splint therapy, residual levels occur in 60% of the patients in the long-term (van Grootel et al., 2017) . The ratio between cases of 'successful'/'unsuccessful' treatment in the long-term is unknown for laser therapy to date. As different inter-therapy ratios between successful/unsuccessful treatments may yield a similar overall outcome of pain variables, conclusions on cost-effectivity will be incomplete when they are solely based on overall outcome. In order to gain information on success rates in the long-term, you'll need a protocol in which each therapy is followed by a follow-up without treatment, of at least 6 months, and even 12 months, at least for those patients whose treatment is successful in the short-term.
Third, general clinical care of TMD is started with counselling and basic education, at least on avoiding possibly harmful habits. A preceding counselling and education has a pronounced influence on the pain level following counselling, and on the outcome of subsequent splint therapy, as has been discussed in van Grootel et al., 2017 . The influence of a preceding counselling and education on laser therapy is unknown to date, but a lack of control of this factor may be related to inconsistencies in the literature regarding the efficacy of laser therapy. Hence, a protocol on comparing laser and splint therapy should include a standardized way of counselling and a collection of base-line values of outcome variable at the intake, and a waiting period of at least 2 weeks for stabilizing the effect of counselling.
You may consider the use of the index 'Treatment-Duration-Control', TDC; van Grootel et al. 2017; van der Glas & van Grootel, BMC Med Res Methodol. 2013; 13:123) for enabling an RCT with a therapyand-patient-dependent number of visits and treatment duration. All three features of treatment outcome, which are relevant for a costseffectiveness analysis, will then be addressed, i.e. (1) the time and number of visits needed to decide whether a patient's treatment is either successful or unsuccessful, (2) success rate, and (3) therapy effectiveness.
Some specific remarks: P6, Table 2 , sample calculation: on which outcome variable and preceding study are 'Experimental mean (1)' and 'Experimental mean (2) and its standard deviations based? Fifteen patients per sample, 45 patients in total, is a small number for attaining stable mean outcome variables without too much fluctuations by chance of the patient composition within samples (for example in the number of patients with acute TMD vs. patients with chronic TMD). Larger sample sizes are also needed for attaining sufficiently accurate information on success rate of therapies.
P6, L51, Inclusion and exclusion criteria: 'Young people between 15 and 25 years of age with a diagnosis of TMD in group I (myofascial pain in accordance with the RDC-TMD) will be included in the study'. However, will people from group I with overlapping TMJ problems be excluded, in accordance with solely laser treatment of jaw muscle locations? (p8, L3) P7, L23: 'For the random distribution of volunteers with TMD, lots will be drawn using duly sealed brown envelopes.' Lists with randomized computer-generated numbers are commonly used, because a good randomizing of a sequence of non-randomized filled envelopes is difficult to attain. Furthermore, some sample stratification might be useful, for example for age, then also avoiding large chance fluctuations in samples of limited size regarding the number of patients with more or less chronic TMD. Very young patients (between 15-20 yrs) will probably have less chance on chronic TMD at the intake.
P8, L17: 'For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.' The laser equipment should be switched on for having the same sound cues. Like in previous studies, a special laser probe which blocks the radiation should be used for the placebo group. 
Please specify the meaning of 'G1' and 'G2' (has been done in Abstract but not in the main text)
Conclusion:
The current study protocol needs major revision as it would prevent a sound interpretation of the data.
VERSION 1 -AUTHOR RESPONSE

Response to Reviewers
Reviewer reports:
Reviewer: 1
Reviewer Name Robert Ćelić 1. Please state any competing interests or state 'None declared': None declared Ans: Thank for you the advice we are going to do this changes.
2.Please leave your comments for the authors below In my opinion, the authors of the manuscript should do a major revision. The suggestions for that are: -The title of the manuscript is a little bit confusing. The authors mentioned "photomodulation" and I think that was the first and last time in the manuscript. Maybe the key words in the title should be: lowlevel laser, occlusal splint, placebo and myofascial TMD pain. Ans: Thank for you the advice we are going to do this changes.
3.The author did not define what kind of muscle pain: acute or chronic pain. The treatment approaches for TMDs are numerous and different. For example, if exists acute pain, after providing any kind of noninvasive treatment (such as LLL, occlusal therapy, placebo or others), pain stops and there is no need for continuation of therapy. In that case, it seems irrational and unnecessary to carry on with the therapy or follow-up the outcomes of the therapy after 3 or 6 months, one year. They provided three types of therapy which can last differently. My suggestion is to use "the average time of treatment" (in months) for every of the three treatment modalities followed-up in this study. As I mentioned earlier, the prerequisite for that is to differentiate the patients in three examined groups as acute or chronic patients. Ans: Thank for you the advice we are going to do this changes.
4. RDC/TMD classification uses diagnoses not signs or symptoms (pain) of TMD. In the Methodology section that fact should be mentioned and better explained. Pain is only one of the symptoms in that diagnosis (myofascial pain). What about the form and range of the mandibular movements (opening, left and right laterotrusion, protrusion)? Ans: The RDC/TMD questionnaire will be responsible to indicate the diagnosis for myofascial TMD and clinical examination form analyzes the mandibular movements. The diagnosis of pain will be evaluated by the Visual Analog Scale (VAS) and quality of life will be determined by applying the adapted EuroQol-5D.
5.What type of occlusal splint did they use to treat myofascial pain? Stabilization splint, protruding splint, distraction splint, placebo splint, or others? Ans: The type of occlusal splint used in this study is Stabilization splint made in hard acrylic fabricated for the maxillary arch.
6.They used some abbreviations in the manuscript which have not been adequately described and could be misleading for the readers (such as LIL, SPIRIT, DTM treatment, UNINOVE, etc).
Ans: Thank for you the advice we are going to do this changes.
7.At the moment, I cannot comment the Result and Discussion sections because there are not present. But if I understood instructions for reviewers from the Editors it is OK for ongoing studies. Ans: Ok.
8. The references have not been written in the style of the Journal and should be checked and adapted to it. Ans: Thank for you the advice we are going to do this changes.
9.I am not native speaker for the English language, so I do not have a merit to judge it. To me, the language "sounds" OK. Ans: Thank you.
10. I would encourage a cost-effective ness analysis of different treatment modalities for myofascial TMD pain, but some clarifications should be done in the manuscript before. OBAAAA Ans: Thank you for you this observation.
Reviewer: 2
Reviewer Name Hilbert van der Glas
General remarks:
1.The aim of the study is (1) to evaluate the effectiveness of treatments with low-intensity laser and occlusal splint for muscle pain in patients with TMD with a placebo sham-laser treatment as control, (2) to determine the direct costs of treatment, and (3) to compare the cost-effectiveness of both types of treatment by determining the ratio between the amount of direct costs and the improvement in an outcome variable of pain intensity. Furthermore, the effect of treatment will be determined on Healthrelated Quality of Life (HR-QoL), using EuroQol (EQ-5D). It is relevant to evaluate clinical and economic data together in sight of decision making and to compare laser treatment with splint therapy (a common type of therapy in Dentistry). Furthermore, it is interesting to carry out sham-laser treatment as placebo, also for comparison with splint therapy. However, clarification and further considerations are needed regarding the following issues. First, laser treatment includes, according to the proposed protocol, an initial phase in which this treatment is applied twice a week for 6 weeks, and then twice a month up to 12 months. Splint therapy includes wearing of an occlusal splint at night for 12 months. However, fixed treatment durations of 12 months are not in accordance with general clinical care. Durations of laser treatment of 2-8 weeks have been reported in the literature while the intended duration of occlusal splint therapy varies between 12-30 weeks; the mean duration of splint therapy is 24.2 weeks (cf. your ref# 40: van Grootel et al., BMC Musculoskeletal Disorders. 2017; 18:76) . Hence, apart from over-treatment of many patients, your proposed long treatment duration of 12 months will yield biased outcomes of cost-effectiveness. Ans:Thank for you the advice we are going to do this changes.
2.Second, it is not sufficient to consider an overall improvement in, for example, pain outcome, because pain and other signs and symptoms of myogenous TMD are reduced to residual levels in only part of the patients, with a 'successful' treatment. Following splint therapy, residual levels occur in 60% of the patients in the long-term (van Grootel et al., 2017) . The ratio between cases of 'successful'/'unsuccessful' treatment in the long-term is unknown for laser therapy to date. As different inter-therapy ratios between successful/unsuccessful treatments may yield a similar overall outcome of pain variables, conclusions on cost-effectivity will be incomplete when they are solely based on overall outcome. In order to gain information on success rates in the long-term, you'll need a protocol in which each therapy is followed by a follow-up without treatment, of at least 6 months, and even 12 months, at least for those patients whose treatment is successful in the short-term. Ans: Thank for you the advice we are going to do this changes.
3.Third, general clinical care of TMD is started with counselling and basic education, at least on avoiding possibly harmful habits. A preceding counselling and education has a pronounced influence on the pain level following counselling, and on the outcome of subsequent splint therapy, as has been discussed in van Grootel et al., 2017 . The influence of a preceding counselling and education on laser therapy is unknown to date, but a lack of control of this factor may be related to inconsistencies in the literature regarding the efficacy of laser therapy. Hence, a protocol on comparing laser and splint therapy should include a standardized way of counselling and a collection of base-line values of outcome variable at the intake, and a waiting period of at least 2 weeks for stabilizing the effect of counselling.
Ans:The present study aims: to estimate the direct costs in the treatment of chronic muscle pain in patients with TMD with photobiomodulation therapy and with occlusal splint and a placebo group; to evaluate the effectiveness of the treatments with photobiomodulation therapy and occlusal splint for muscle pain in patients with TMD.
4.You may consider the use of the index 'Treatment-Duration-Control', TDC; van Grootel et al. 2017; van der Glas & van Grootel, BMC Med Res Methodol. 2013; 13:123) for enabling an RCT with a therapy-and-patient-dependent number of visits and treatment duration. All three features of treatment outcome, which are relevant for a costs-effectiveness analysis, will then be addressed, i.e. (1) the time and number of visits needed to decide whether a patient's treatment is either successful or unsuccessful, (2) success rate, and (3) therapy effectiveness. Ans: Thank for you the advice.
Some specific remarks:
5.P6, Table 2 , sample calculation: on which outcome variable and preceding study are 'Experimental mean (1)' and 'Experimental mean (2) and its standard deviations based? Fifteen patients per sample, 45 patients in total, is a small number for attaining stable mean outcome variables without too much fluctuations by chance of the patient composition within samples (for example in the number of patients with acute TMD vs. patients with chronic TMD). Larger sample sizes are also needed for attaining sufficiently accurate information on success rate of therapies. Ans: The sample calculation was based on a previous literature review and will only be included in the sample, patients with chronic myofascial pain.
6.P6, L51, Inclusion and exclusion criteria: 'Young people between 15 and 25 years of age with a diagnosis of TMD in group I (myofascial pain in accordance with the RDC-TMD) will be included in the study'. However, will people from group I with overlapping TMJ problems be excluded, in accordance with solely laser treatment of jaw muscle locations? (p8, L3) Ans: Inclusion Criteria: Young people between 15 and 25 years of age with a diagnosis of TMD in group I (Chronic myofascial pain in accordance with the RDC-TMD) will be included in the study. Exclusion Criteria: Individuals with dental-facial anomalies who were in orthodontic or orthopedic treatment of the jaws or in psychological or physical therapy will be excluded. Individuals who were taking muscle relaxants or anti-inflammatory medications will also be excluded.
7. P7, L23: 'For the random distribution of volunteers with TMD, lots will be drawn using duly sealed brown envelopes.' Lists with randomized computer-generated numbers are commonly used, because a good randomizing of a sequence of non-randomized filled envelopes is difficult to attain. Furthermore, some sample stratification might be useful, for example for age, then also avoiding large chance fluctuations in samples of limited size regarding the number of patients with more or less chronic TMD. Very young patients (between 15-20 yrs) will probably have less chance on chronic TMD at the intake. Ans: Thank for you the advice we are going to do this change.
8. P8, L17: 'For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.' The laser equipment should be switched on for having the same sound cues. Like in previous studies, a special laser probe which blocks the radiation should be used for the placebo group. Ans: For the placebo group, all the measures described for the group 1 (photobiomodulation) will be adopted, however the laser equipment will remain switched off. But the same sound of the equipment will be simulated and a guide light will be on.The placebo group will also have the same follow-up of visits that group 1.
9.P8, L41: 'Muscle pain will be analysed by clinical criteria of the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)'. This analysis need to be specified. RDC/TMD uses a 0-10 pnt VAS for recording spontaneous pain, and 0-3 pnt scales for scoring pain following palpation of various jaw muscle locations. Previous studies on laser therapy usually use one type of VAS, i.e. 0-10 pnt scales for the various outcome variable of pain, without summarizing them. In order to facilitate inter-study comparisons, it is useful to present pre-and post-treatment mean values and SDs, and Cohen's d-values of size effect. If you would consider the use of the index of 'Treatment-Duration-Control; TDC), patient-specific scores from 0-10 pnt VASs can be considered with an SDD threshold of 5 points for selection as initial reference items (5/10 pnts > 47 %-scale units), and 6 points for added reference items (6/10 pnts > 55 %-scale units). TDC values (the mean of contrast-values) summarizes treatment outcome in a patientspecific way. Ans: Thank for you the advice we are going to do this change.
10.P8, L51: 'To assess the impact of treatment on the quality of life of the participants, the EQ-5D will be used, which is a generic instrument for assessing quality of life related to health, developed in Europe, translated and validated for several languages, including Portuguese [35] . Because it was developed for the purpose of determining a single cardinal indicator of the state of health, it can be used for both clinical evaluation and economic evaluation.' Such an evaluation is important indeed for an inter-study comparison of gain in HR-QoL, but how does your analysis of HR-QoL looks like? Apart from calculating the ratio costs/unit of pain improvement, are you going to determine the ratio between gain in qual scores and pain improvement? Ans: Thank for you the advice we are going to do this change.
11.P9, L28: 'Cost Analysis'. Apart from direct treatment costs, doe absenteeism from work plays a role? Furthermore, what about travel costs and availability of therapies, including relationship with travel distance in Brazil? Ans: It is a preliminary cost-effectiveness study, so we opted to analyze only direct costs.
12.P10, L3: 'Analyses: (CG1/PAING1)-(CG2/PAING2) CE (cost-effectiveness) = (CG1 -CG2)/ (PAING1 -PAING2)'
Please specify the meaning of 'G1' and 'G2' (has been done in Abstract but not in the main text) Ans: Thank for you the advice we are going to do this change.
13.Conclusion:
The current study protocol needs major revision as it would prevent a sound interpretation of the data. Ans: Thank for you the advice we are going to do this change.
VERSION 2 -REVIEW REVIEWER
Hilbert van der Glas
The Dental School, University of Dundee, UK REVIEW RETURNED 24-Nov-2017
GENERAL COMMENTS Manuscript ID bmjopen-2017-018326-R1 entitled "PHOTOMODULATION IN THE TREATMENT OF PAIN IN PATIENTS WITH TEMPOROMANDIBULAR DISORDERS: PROTOCOL FOR COST-EFFECTIVENESS ANALYSIS"
Response from reviewer #2
Some but not all remarks from my previous report have been addressed; some remarks need further attention.
First, Treatment duration (p6 f.) has been reduced from 12 months to 6 weeks for laser-Tx and to 6 months for splint-Tx (hence 26 weeks for splint-Tx). Without any rationale, these durations seem to be arbitrary (for splint-Tx longer than average). Thus please, consider this issue again and add a rationale. Furthermore, choosing a fixed long duration for splint-Tx maybe unethical. What are you going to do with patients whose are hardly or not responsive to splint-Tx following the first 12 weeks? If you would continue with splint-Tx without altering treatment, such patients are at risk to become permanently chronic pain patients.
Second, I have previously put forward the issue: "general clinical care of TMD is started with counselling and basic education, at least on avoiding possibly harmful habits. A preceding counselling and education has a pronounced influence on the pain level following counselling, and on the outcome of subsequent splint therapy, as has been discussed in van Grootel et al., 2017 . The influence of a preceding counselling and education on laser therapy is unknown to date, but a lack of control of this factor may be related to inconsistencies in the literature regarding the efficacy of laser therapy. Hence, a protocol on comparing laser and splint therapy should include a standardized way of counselling and a collection of base-line values of outcome variable at the intake, and a waiting period of at least 2 weeks for stabilizing the effect of counselling.". You have answered: "The present study aims: to estimate the direct costs in the treatment of chronic muscle pain in patients with TMD with photobiomodulation therapy and with occlusal splint and a placebo group; to evaluate the effectiveness of the treatments with photobiomodulation therapy and occlusal splint for muscle pain in patients with TMD.
However, my point is that it is known from the literature (cf. Discussion in van Grootel et al., 2017 ; your current reference #38) that splint-Tx has hardly any effect without preceding counseling.
The combination of preceding counseling and splint-Tx is very effective, more than counseling alone. Because (1) common clinical care of TMD starts with counseling (and basic education), (2) your study on cost-effectiveness is expected to be related to such care, and (3) for ethical reasons, splint-Tx should be preceded by a standardized type of counseling of which the stabilized effect is also recorded after a waiting time of 2 weeks. Furthermore, the same type of counseling should precede laser-Tx and the placebo-laserTx, the more as basic education serves as a first backup in common clinical care for self-managing of TMD pain in the long-term.
Some specific remarks left: P5, top (also Table 2 ), sample calculation: It is not clear on which references 'a previous literature review' is based (p5, L7). Apart from the outcome of a power calculation, 15 patients per sample, 45 patients in total, is a small number for attaining stable mean outcome variables without too much fluctuations by chance of the patient composition within samples (for example in the number of patients which are well responsive ('succesful Tx') or none or hardly responsive ('unsuccessful Tx'); your chronic pain patients will in part be hardly responsive). Larger sample sizes are also needed for attaining sufficiently accurate information on success rate of therapies. With 15 patients per sample you'll have coarse discrete changes of >5%. Furthermore, larger sample sizes are also needed to account for drop-outs; you'll need samples of at least 25 patients.
My previous remark about Inclusion and exclusion criteria (p 6, L11 f.): 'Young people between 15 and 25 years of age with a diagnosis of TMD in group I (….) will be included in the study'. However, will people from group I with overlapping TMJ problems be excluded, in accordance with solely laser treatment of jaw muscle locations?) You have answered: "Inclusion Criteria: Young people between 15 and 25 years of age with a diagnosis of TMD in group I (Chronic myofascial pain in accordance with the RDC-TMD) will be included in the study. Exclusion Criteria: Individuals with dental-facial anomalies who were in orthodontic or orthopedic treatment of the jaws or in psychological or physical therapy will be excluded. Individuals who were taking muscle relaxants or anti-inflammatory medications will also be excluded." However, my point is that you should confine your patient selection to samples with solely group I diagnosis, without overlap with problems in the Temporomandibular Joint (group II or III diagnosis) which is possible in RDC-TMD (for example see Kraus et al., 2014; ref#44 in van Grootel et al., 2017 your ref # 38) . Such a selection will be consistent with treatment of solely jaw muscle location with laserTx in your protocol.
A small point: P7, L10: 'Twelve laser applications will be applied as initial treatment …..'. The word "initial" should be omitted as laser-Tx is confined to two weeks.
Language:
Although not being a native speaker, your English text seems in general all right to me. However, I noticed two complicated sentences at two locations in the manuscript, which do not run well:
(1) p3, bottom, 'Because this is ……..recommendations', and (2) p5, L6, "The sample calculation …" Conclusion: Some further revision of the study protocol is required.
REVIEWER
Robert Ćelić
Department of Removable Prosthodontics, School of Dental Medicine University of Zagreb, Ivana Gundulića 5, 10000 Zagreb, Croatia REVIEW RETURNED 29-Nov-2017
GENERAL COMMENTS
In my opinion the author should change: -in the title, to add "chronic pain" instead of "pain" -in discussion, spelling error "painfull" to change in "painful" -in the reference section, the author should to check the way how they wrote the name of the journal. They should follow the style of the BMJ Open Journal (no dots). The authors did correct almost all the remarks what I have been suggested in the first revision process.
VERSION 2 -AUTHOR RESPONSE
Response to Reviewers Reviewer: 2
Reviewer Name Hilbert van der Glas Reviewer reports:
Some but not all remarks from my previous report have been addressed; some remarks need further attention. Ans: We appreciate the comments and suggestions and have made the adjustments as requested. The changes are listed below and marked in the article. 1. First, Treatment duration (p6 f.) has been reduced from 12 months to 6 weeks for laser-Tx and to 6 months for splint-Tx (hence 26 weeks for splint-Tx). Without any rationale, these durations seem to be arbitrary (for splint-Tx longer than average). Thus please, consider this issue again and add a rationale. Furthermore, choosing a fixed long duration for splint-Tx maybe unethical. What are you going to do with patients whose are hardly or not responsive to splint-Tx following the first 12 weeks? If you would continue with splint-Tx without altering treatment, such patients are at risk to become permanently chronic pain patients. Ans: After analysis and consideration of the reviewers, the text and methodology were adjusted and the references indicated in the text. The duration of treatment was determined and justified according clinical studies. The changes are indicated in yellow in the text.
Procedures
The treatments' protocols of photobiomodulation and occlusal splint presented in this study are based on clinical trials 8 16 29 32. The participants of three groups will be received standard information about TDM, the complex cause of the pain and the possible contributing factors. The patients will be counselling on avoid possibly stress-induced habits of grinding, clenching, nail biting or biting on objects like pencils, excessive gum chewing, biting and/or sucking on the lip or cheek, and pressing and/or sucking on the tongue 33. The baseline of this study will be 02 weeks after the patients received standard information. After 2 weeks each treatment( G1, G2, G3) will be start; if the patient does not respond to treatment (nonresponder), this patients will be excluded from the research sample, but the researchers will be offered the alternative treatment method. The patients who do not respond will be treated according their needs with integral treatment (with psychologists, physiotherapists, and so on). As these data are very important, the number of patients withdrawn from the study will be computed and included in the intention to treat analysis (ITT). At the end of the research, all patients will be treated integrally to resolve the major cause that causes this disorder.
Treatment with Photobiomodulation
For the Photobiomodulation Therapy, a gallium-aluminum-arsenide (GaAIAs) laser, model Twin Flex Evolution ®, from MM Optics, will be used. The laser therapy sessions will be performed in a reserved room, annexed to the dental clinic offices, free from sound interference. At the time of application, only the volunteer to be treated and the professional responsible will be present, both wearing special glasses for eye protection. The tip of the laser will be coated with disposable transparent plastic (PVC) (to avoid cross-contamination and for reasons of hygiene) and the facial site to be irradiated will be cleansed with 70% alcohol. During the applications the patient will remain seated, with the Frankfurt plane parallel to the ground. Twelve laser applications will be applied, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol.8 16 29 The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face.16 29 The patients were called back for follow-up visits on 1, 3 ,6 and 12 months after the last day of photobiomodulation therapy.
Treatment with Occlusal Splints
The type of occlusal splint used in this study is Stabilization splint made in hard acrylic fabricated for the maxillary arch. The splints will be made following the principles established by literature.1 Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate splint will be made, to be later replaced with acrylic resin 34, and these splints will be adjusted in centric relation, to promote occlusal stability and disocclusion guide. 35 The group undergoing treatment with occlusal splints will be instructed to use the device during sleep, 8 hours per night. The splints will be check after 2 weeks of use and adjusted them, if needed. The patients will be asked to use the occlusal splints according mentioned and return 3 months after treatment. If in this return the patient did not respond to treatment (nonresponder), the researchers will be offer the alternate treatment method, but these patients will be excluded of the research sample. The respond patients will be continuing to use the occlusal splint and return to the 06 months follow-up visit.32 2. Second, I have previously put forward the issue: "general clinical care of TMD is started with counselling and basic education, at least on avoiding possibly harmful habits. A preceding counselling and education has a pronounced influence on the pain level following counselling, and on the outcome of subsequent splint therapy, as has been discussed in van Grootel et al., 2017 . The influence of a preceding counselling and education on laser therapy is unknown to date, but a lack of control of this factor may be related to inconsistencies in the literature regarding the efficacy of laser therapy. Hence, a protocol on comparing laser and splint therapy should include a standardized way of counselling and a collection of base-line values of outcome variable at the intake, and a waiting period of at least 2 weeks for stabilizing the effect of counselling.". You have answered: "The present study aims: to estimate the direct costs in the treatment of chronic muscle pain in patients with TMD with photobiomodulation therapy and with occlusal splint and a placebo group; to evaluate the effectiveness of the treatments with photobiomodulation therapy and occlusal splint for muscle pain in patients with TMD.
intensity as a main outcome variable and not EMG variables of which mean and SD values before and after Tx may be quite different. Hence, the power assessment should be based on mean and SD values of such VAS-scores from previous studies. An interesting previous study in this respect is the one of Walund et al, 2015 (your ref#32), which includes means and SDs of VAS-data from adolescent TMD patients. Walund et al. have concluded that, including a drop-out of 10%, 33 patients would be necessary for each subgroup. Since Walund et al. used two subgroups rather than three subgroups in your study (for which more rather than less patients will be needed), you should re-assess statistical power using either the VAS-data of pain intensity of Walund et al. or your own VAS-data from previous studies on adolescents.
Conclusion: An entire revision of your assessment of statistical power is essential. For the rest, I have no remaining remarks.
VERSION 3 -AUTHOR RESPONSE
Response to Reviewers
Reviewer Name Hilbert W. van der Glas
The current version of your manuscript has been much improved by (1) the way you'll deal with nonresponders to the intended treatment, (2) including initially counselling and a waiting time of 2 weeks, and (3) selecting patients with solely group I diagnosis of RDC/TMD.
Regarding the sample size for sufficient statistical power, 15 patients for three subgroups (45 patients in total), you currently refer to three references, i.e. (1) Venezian et al., 2010 , your ref #16, (2) Godoy et al., 2013 , ref#29, and (3) De Carli et al., 2016 . Study#30 uses only 8 patients for laser-Tx and 7 patients for Botox-Tx respectively, without rationale. Study#16 uses 12 patients for each of 4 subgroups (48 patients in total), also without rationale. However, study#29 (de Godoy et al.) uses EMG data from study#16 for calculating statistical power. Actually, the same EMG data used in study#29 have also been used for the statistical power assessment for the present study; these EMG data (mean and SD) are presented in Table 2 (de Godoy is also a co-author of the present study), yielding the conclusion that 15 patients would be sufficient per subgroup. However, such a procedure and conclusion is not warranted because the present study uses VAS-scores of pain intensity as a main outcome variable and not EMG variables of which mean and SD values before and after Tx may be quite different. Hence, the power assessment should be based on mean and SD values of such VAS-scores from previous studies.
An interesting previous study in this respect is the one of Walund et al, 2015 (your ref#32), which includes means and SDs of VAS-data from adolescent TMD patients. Walund et al. have concluded that, including a drop-out of 10%, 33 patients would be necessary for each subgroup. Since Walund et al. used two subgroups rather than three subgroups in your study (for which more rather than less patients will be needed), you should re-assess statistical power using either the VAS-data of pain intensity of Walund et al. or your own VAS-data from previous studies on adolescents.
